For two years running, the Hardman & Co Healthcare index has declined, underperforming both the FTSE 100 and the FTSE All-Share indices. This is quite unusual for healthcare stocks. Apart from the general economic influences, which have made institutions more risk-averse, there was a common knowledge that several companies were in need of additional working capital; so, share prices were marked down in anticipation of equity raises. However, the small- and mid-cap life sciences sector has alway...
13th June 2023 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objecti...
22nd May 2023 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectiv...
17 March 2023 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectiv...
Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked....
Yourgene Health is an international molecular diagnostics group which develops & commercialises genetic products & services, mainly in the area of reproductive health. It works in partnership with global leaders in DNA technology to advance diagnostic science & positively impact human health. Taking advantage of growth in the molecular diagnostics market The molecular diagnostics market had a global value of $8.3 billion in 2019 and is forecast to grow at a CAGR of 9% up to 2026, according...
Hardman & Co Research Hardman & Co Research: Yourgene Health (YGEN): EBITDA-positive in fiscal 2020 22-Feb-2019 / 10:00 GMT/BST Hardman & Co: EBITDA-positive in fiscal 2020 Yourgene Health (YGEN) is an international molecular diagnostics group that uses the latest advances in DNA sequencing technology for non-invasive prenatal screening tests (NIPT). Its flagship IONA test uses complex statistical analyses to determine the likelihood that a fetus is carrying a genetic disorder, such as Down's syndrome. YGEN has been held back by a patent infringement case and a complicated balance sheet. H...
Hardman & Co Research Hardman & Co Research: Yourgene Health (YGEN): Transformed and de-risked 19-Feb-2019 / 07:15 GMT/BST Hardman & Co: Transformed and de-risked Yourgene Health (YGEN) is an international molecular diagnostics group that uses the latest advances in DNA sequencing technology for non-invasive prenatal screening tests (NIPT). Its flagship IONA test uses complex statistical analyses to determine the likelihood that a fetus is carrying a genetic disorder, such as Down's syndrome. YGEN has been held back by a patent infringement case and a complicated balance sheet. However, se...
In the March 2018 edition of the Hardman Monthly Newsletter, Nigel Hawkins addresses the attractions of quoted infrastructure funds that maintain a low profile. Over the next decade, infrastructure investment levels will remain high, especially in the energy, utilities and railways sectors. As such, infrastructure funds are well-placed to benefit from this trend. These funds, three of which are valued by the market at over £2bn, have been resilient performers over the last five years, althou...
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind...
​Premaitha uses the latest advances in DNA sequencing technology for non-invasive prenatal screening tests. IONA estimates the risk that a fetus has any of Down’s, Edwards’ or Patau’s syndromes caused by a genetic abnormality. Although IONA is entering a competitive and litigious market, it has some advantages, is CE Marked and is the first to win a UK NHS contract. Premaitha is subject to distracting IP infringement claims but 1H’16 results showed early signs of commercial traction wh...
​Premaitha is a molecular diagnostics company that has used the latest advances in DNA technology to develop a non-invasive pre-natal screening test. IONA is its first test, for detection of genetic defects to estimate the risk that a foetus is carrying a disorder, such as Down’s syndrome. Although IONA is entering a competitive market, it does have some advantages and is the first test to be regulatory approved via a CE Mark. Interim results show the first signs of commercial traction which...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.